Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck
21.9.2022 14:00:00 EEST | Business Wire | Press release
Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293.
PARP (poly (ADP-ribose) polymerase) is key in the repair of DNA damage and PARP inhibitors have been shown to be highly efficacious in the treatment of tumors deficient in homologous recombination repair, such as breast, ovarian, prostate and pancreatic cancers which are BRCA mutated.
NMS-293 is an orally available PARP1 inhibitor, designed to be more PARP1 selective and brain penetrant compared to first generation PARP inhibitors. With its expected lower hematological side effect profile, it has the expected features for potential use not only as single agent but also in combination with DNA-damage accumulating agents in a wide range of tumors. NMS-293 is currently in early clinical development for the treatment of patients with BRCA mutated tumors as single agent and with recurrent Glioblastoma (GBM), a brain tumor with very high medical need, in combination with temozolomide (TMZ).
Under the current agreement, Merck will make early payments (up-front and option exercise fees) of up to US$65 million to NMS. Furthermore, NMS will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck. Upon exercise of the option, NMS will grant to Merck the exclusive rights to research, develop, manufacture, and commercialize NMS-293.
“NMS-293 is the first next-generation PARP1 inhibitor to enter clinical trials. Based on its unique features, NMS-293 has strong potential in combination with a wide variety of DNA-damage accumulating agents, such as chemotherapy, DNA repair inhibitors or ADCs, in tumor settings that are precluded to current PARP inhibitors, such as brain tumors, and where there is an urgent global need to find treatments,” stated Hugues Dolgos, Pharm.D., chief executive officer of NMS and NMS Group. “NMS has built a unique and proprietary platform of first-in-class and best-in-class assets and expanded to new target classes like PARP with NMS-293 as our flagship. We believe that Merck, a global leader in DNA repair with a well-established commercialization footprint, is the ideal partner to maximize the value of our program.”
Building on the therapeutic impact that PARP inhibitors have had over the last several years, we believe this new PARP1 program, if successful, could fill a significant unmet need for patients unresponsive to existing PARP inhibitors with an improved hematological adverse event profile,” said Victoria Zazulina, M.D., Head of Development Unit Oncology for the Healthcare business of Merck. “The work of NMS to discover and advance this next generation PARP1 selective inhibitor coupled with our deep expertise in developing therapies which modify DNA damage response mechanisms, creates a strong foundation to further develop this investigational therapy for patients.”
During the option period, NMS and Merck will collaborate on the clinical development of NMS-293 as monotherapy and in combination, with NMS designing, sponsoring, conducting, and funding global clinical trials.
About NMS-293
NMS-293 is an orally available small molecule inhibitor of PARP1 and is currently in early clinical development for the treatment of patients with BRCA mutated tumors as single agent and with recurrent Glioblastoma (GBM), a brain tumor with very high medical need, in combination with temozolomide (TMZ).
About Nerviano Medical Sciences
Nerviano Medical Sciences S.r.l. (NMS Srl) is focused on discovery and clinical development of small-molecule new chemical entities (NCEs) for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs originating from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in-house and with partners.
NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Our experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing).
A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.
We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.
About NMS Group
NMS Group is the largest oncological R&D company in Italy. More than half of our 400 employees are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.
NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug products supporting clinical developments and commercialization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005071/en/
Contact information
Media contact: Sidney Dung Sidney.dung@nmsgroup.it
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release
Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release
Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release
NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 19:40:00 EET | Press release
Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redundant Command and Data Handling systems as well as the Instrument Command and Data Handling systems for both the Wide Field Instrument and Coronagraph Instrum
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 17:05:00 EET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
